Ovarian Cancer

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.

Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.

Phase III data from the ARIEL3 trial showed that rucaparib (Rubraca) improved progression-free survival versus placebo as a maintenance treatment for women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer.

The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.

Michael J. Birrer, MD, PhD, discusses some of the exciting data presented at the 2017 ASCO Annual Meeting, especially with olaparib (Lynparza) in SOLO2, and what other emerging advancements are poised to transform the landscape.

Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853) induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.

Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

In follow-up results to data first presented in December 2016, investigators found that the combination of olaparib (Lynparza) and cediranib maleate continued to show superior progression-free survival compared with olaparib alone for women with BRCA-negative recurrent platinum-sensitive ovarian cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.

Foundation Focus CDx BRCA, can detect both germline and somatic BRCA1/2 mutations in women with ovarian cancer who are candidates for the PARP inhibitor rucaparib (Rubraca).

Randomization designed to isolate the impact of a specific factor has enabled practitioners to understand the value, or lack of value of particular drugs, procedures, or processes in a given clinical setting.

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.

Patients with proliferative or mesenchymal ovarian tumors treated with bevacizumab (Avastin) had superior progression-free survival and a trend toward improved overall survival compared with patients with immunoreactive or differentiated tumors.

Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.

Adding bevacizumab to standard platinum-based chemotherapy was associated with a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Preclinical findings showed that the combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma ovarian tumor cells.

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

Within the last 30 days of life, black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care, according to results recently published in the Journal of Clinical Oncology.

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.